PSEN1 and Mental deterioration: In our study, 3-month-old APP/PS1 mice showed no difference in cognitive performance, synaptic and C1q levels compared with WT mice (Supplementary Fig. 5), and A16 treatment did not induce cognitive decline (Supplementary Fig. 5a, b), neuroinflammation (Supplementary Fig. 6) and microglial synapse engulfment (Supplementary Fig. 7) in 3-month-old APP/PS1 mice when relative to APP/PS1 controls.